Combined Holdings of ATAI Life Sciences (ATAI) - Updated Daily
Psychedelic Therapy
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 0% | $300.48m |
| 🏋️♀️Weight Rank Across All Funds | 🌏Country |
| 208 | 🇺🇸United States |
| 💳ARK Estimated Cost Average | 🎫ARK Ownership Percent |
$4.94 - ARKG | 0% |
| Description | |
|---|---|
| atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. atai's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders. atai's mission is to bridge the gap between what the mental healthcare system currently provides and what patients need. atai is headquartered in Berlin, with offices in New York and London. | |
| Website | |
| www.atai.life |
Other ETFs That Hold ATAI
Research Notes and Commentary for ATAI
No Research Notes Found for ATAI